

1 CLAIMS

2 What is claimed is:

3  
4 Claim 1. A biopolymer marker selected from the group  
5 consisting of sequence ID (R)LPSFVMSLAMMAVAR(G),  
6 QVGPDNTGEYRCR or at least one analyte thereof useful in  
7 indicating at least one particular disease state.

8  
9 Claim 2. The biopolymer marker of claim 1 wherein  
10 said disease state is predictive of Alzheimers disease.

11  
12 Claim 3. A method for evidencing and categorizing at  
13 least one disease state comprising:

14 obtaining a sample from a patient;  
15 conducting mass spectrometric analysis on said  
16 sample;  
17 evidencing and categorizing at least one biopolymer  
18 marker sequence or analyte thereof isolated from said  
19 sample; and,

20 comparing said at least one isolated biopolymer  
21 marker sequence or analyte thereof to the biopolymer  
22 marker sequence as set forth in claim 1;

23 wherein correlation of said isolated biopolymer  
24 marker and said biopolymer marker sequence as set forth in

1 claim 1 evidences and categorizes said at least one  
2 disease state.

3  
4 Claim 4. The method of claim 3, wherein said step  
5 of evidencing and categorizing is particularly directed to  
6 biopolymer markers or analytes thereof linked to at least  
7 one risk of disease development of said patient.

8  
9 Claim 5. The method of claim 3, wherein said step  
10 of evidencing and categorizing is particularly directed to  
11 biopolymer markers or analytes thereof related to the  
12 existence of a particular disease state.

13  
14 Claim 6. The method of claim 3, wherein the sample  
15 is an unfractionated body fluid or a tissue sample.

16  
17  
18 Claim 7. The method of claim 3, wherein said sample  
19 is at least one of the group consisting of blood, blood  
20 products, urine, saliva, cerebrospinal fluid, and lymph.

21  
22 Claim 8. The method of claim 3, wherein said mass  
23 spectrometric analysis is selected from the group  
24 consisting of Surface Enhanced Laser Desorption Ionization

1 (SELDI) mass spectrometry (MS), Maldi Qq TOF, MS/MS,  
2 TOF-TOF, and ESI-Q-TOF or an ION-TRAP.

3  
4 Claim 9. The method of claim 3, wherein said  
5 patient is a human.

6  
7 Claim 10. A diagnostic assay kit for determining  
8 the presence of the biopolymer marker or analyte thereof  
9 of claim 1 comprising:

10 at least one biochemical material which is capable of  
11 specifically binding with a biomolecule which includes at  
12 least said biopolymer marker or analyte thereof, and

13 means for determining binding between said  
14 biochemical material and said biomolecule;

15 whereby at least one analysis to determine a presence  
16 of a marker, analyte thereof, or a biochemical material  
17 specific thereto, is carried out on a sample.

18  
19 Claim 11. The diagnostic assay kit of claim 10,  
20 wherein said biochemical material or biomolecule is  
21 immobilized on a solid support.

22  
23 Claim 12. The diagnostic assay kit of claim 10  
24 including:

1 at least one labeled biochemical material.

2  
3 Claim 13. The diagnostic assay kit of claim 10,  
4 wherein said biochemical material is an antibody.  
5

6 Claim 14. The diagnostic assay kit of claim 12,  
7 wherein said labeled biochemical material is an antibody.  
8

9 Claim 15. The diagnostic assay kit of claim 10,  
10 wherein the sample is an unfractionated body fluid or a  
11 tissue sample.  
12

13 Claim 16. The diagnostic assay kit of claim 10,  
14 wherein said sample is at least one of the group  
15 consisting of blood, blood products, urine, saliva,  
16 cerebrospinal fluid, and lymph.  
17

18 Claim 17. The diagnostic assay kit of claim 10,  
19 wherein said biochemical material is at least one  
20 monoclonal antibody specific therefore.  
21

22 Claim 18. A kit for diagnosing, determining risk-  
23 assessment, and identifying therapeutic avenues related to  
24 a disease state comprising:

1 at least one biochemical material which is capable of  
2 specifically binding with a biomolecule which includes at  
3 least one biopolymer marker selected from the group  
4 consisting of sequence ID (R)LPSFVMSLAMMAVAR(G),  
5 QVGPDNTGEYRCR or at least one analyte thereof related to  
6 said disease state; and

7 means for determining binding between said  
8 biochemical material and said biomolecule;

9 whereby at least one analysis to determine a presence  
10 of a marker, analyte thereof, or a biochemical material  
11 specific thereto, is carried out on a sample.

12  
13 Claim 19. The kit of claim 18, wherein said  
14 biochemical material or biomolecule is immobilized on a  
15 solid support.

16  
17 Claim 20. The kit of claim 18 including:  
18 at least one labeled biochemical material.

19  
20 Claim 21. The kit of claim 18, wherein said  
21 biochemical material is an antibody.

22  
23 Claim 22. The kit of claim 20, wherein said labeled  
24 biochemical material is an antibody.

1           Claim 23. The kit of claim 18, wherein the sample is  
2 an unfractionated body fluid or a tissue sample.

3  
4           Claim 24. The kit of claim 18, wherein said sample  
5 is at least one of the group consisting of blood, blood  
6 products, urine, saliva, cerebrospinal fluid, and lymph.

7  
8           Claim 25. The kit of claim 18, wherein said  
9 biochemical material is at least one monoclonal antibody  
10 specific therefore.

11  
12           Claim 26. The kit of claim 18, wherein said  
13 diagnosing, determining risk assessment, and identifying  
14 therapeutic avenues is carried out on a single sample.

15  
16           Claim 27. The kit of claim 18, wherein said  
17 diagnosing, determining risk assessment, and identifying  
18 therapeutic avenues is carried out on multiple samples  
19 such that at least one analysis is carried out on a first  
20 sample and at least another analysis is carried out on a  
21 second sample.

22  
23           Claim 28. The kit of claim 27, wherein said first  
24 and second samples are obtained at different time periods.

1           Claim 29. Polyclonal antibodies produced against a  
2   marker sequence ID selected from the group consisting of  
3   sequence ID (R)LPSFVMSLAMMAVAR(G), QVGPDNTGEYRCR or at  
4   least one analyte thereof in at least one animal host.

5  
6           Claim 30. An antibody that specifically binds a  
7   biopolymer including a marker selected from the group  
8   consisting of sequence ID (R)LPSFVMSLAMMAVAR(G),  
9   QVGPDNTGEYRCR or at least one analyte thereof.

10  
11          Claim 31. The antibody of claim 30 that is a  
12   monoclonal antibody.

13  
14          Claim 32. The antibody of claim 30 that is a  
15   polyclonal antibody.

16  
17          Claim 33. A process for identifying therapeutic  
18   avenues related to a disease state comprising:  
19       conducting an analysis as provided by the kit of  
20   claim 18; and  
21       interacting with a biopolymer selected from the group  
22   consisting of sequence ID (R)LPSFVMSLAMMAVAR(G),  
23   QVGPDNTGEYRCR or at least one analyte thereof;  
24       whereby therapeutic avenues are developed.

1  
2           Claim 34.    The process for identifying therapeutic  
3 avenues related to a disease state in accordance with  
4 claim 33, wherein said therapeutic avenues regulate the  
5 presence or absence of the biopolymer selected from the  
6 group consisting of sequence ID (R)LPSFVMSLAMMAVAR(G),  
7 QVGPDNTGEYRCR or at least one analyte thereof.  
8

9           Claim 35.    The process for identifying therapeutic  
10 avenues related to a disease state in accordance with  
11 claim 33, wherein said therapeutic avenues developed  
12 include at least one avenue selected from a group  
13 consisting of 1)utilization and recognition of said  
14 biopolymer markers, variants or moieties thereof as direct  
15 therapeutic modalities, either alone or in conjunction  
16 with an effective amount of a pharmaceutically effective  
17 carrier; 2)validation of therapeutic modalities or disease  
18 preventative agents as a function of biopolymer marker  
19 presence or concentration; 3)treatment or prevention of a  
20 disease state by formation of disease intervention  
21 modalities; 4)use of biopolymer markers or moieties  
22 thereof as a means of elucidating therapeutically viable  
23 agents, 5)instigation of a therapeutic immunological  
24 response; and 6) synthesis of molecular structures related

1 to said biopolymer markers, moieties or variants thereof  
2 which are constructed and arranged to therapeutically  
3 intervene in said disease state.  
4

5 Claim 36. The process for identifying therapeutic  
6 avenues related to a disease state in accordance with  
7 claim 35, wherein said treatment or prevention of a  
8 disease state by formation of disease intervention  
9 modalities is the formation of biopolymer/ligand  
10 conjugates which intervene at receptor sites to prevent,  
11 delay or reverse a disease process.  
12

13 Claim 37. The process for identifying therapeutic  
14 avenues related to a disease state in accordance with  
15 claim 35, wherein said means of elucidating  
16 therapeutically viable agents includes use of a  
17 bacteriophage peptide display library or a bacteriophage  
18 antibody library.  
19

20 Claim 38. A process for regulating a disease state  
21 by controlling the presence or absence of a biopolymer  
22 selected from the group consisting of sequence ID  
23 (R) LPSFVMSLAMMAVAR(G), QVGPDNTGEYRCR or at least one  
24 analyte thereof.